Treatment > Monoclonal Antibodies

Abstract

Udo Vanhoefer, Mitra Tewes, Federico Rojo, Olaf Dirsch, Norbert Schleucher, Oliver Rosen, Joachim Tillner, Andreas Kovar, Ada H. Braun, Tanja Trarbach, Siegfried Seeber, Andreas Harstrick, José Baselga

From the Department of Internal Medicine (Cancer Research), West German Cancer Center, and the Department of Pathology, University of Essen Medical School, Essen; Merck KGaA, Darmstadt, Germany; and the Laboratory of Oncology Research, Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain. Address reprint requests to Udo Vanhoefer, MD, PhD, Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Hufelandstr 55, 45122 Essen, Germany; e-mail: udo.vanhoefer@uni-essen.de

Purpose. To investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with solid tumors that express epidermal growth factor receptor (EGFR).

Patients and Methods. This was a phase I dose-escalation trial of EMD72000 in patients with advanced, EGFR-positive, solid malignancies that were not amenable to any established chemotherapy or radiotherapy treatment. 
EMD72000 was administered weekly without routine premedication until disease progression or unacceptable toxicity.

Results. Twenty-two patients were treated with EMD72000 at five different dose levels (400 to 2,000 mg/wk). 
National Cancer Institute common toxicity criteria grade 3 headache and fever occurring after the first infusion were dose limiting at 2,000 mg/wk; thus, the maximum-tolerated dose was 1,600 mg/wk. 
No other severe side effects, especially no allergic reactions or diarrhea, were observed. 
Acneiform skin reaction was the most common toxicity, but it was mild, with grade 1 in 11 patients (50%) and grade 2 in three patients (14%). 
Pharmacokinetic analyses demonstrated a predictable pharmacokinetic profile for EMD72000. 
Pharmacodynamic studies on serial skin biopsies revealed that EMD72000 effectively abrogated EGFR-mediated cell signaling (eg, reduced phosphorylation of EGFR and mitogen-activated protein kinase), with no alteration in total EGFR protein. 
Objective responses (23%; 95% CI, 8% to 45%) and disease stabilization (27%; 95% CI, 11% to 50%) were achieved at all dose levels, and responding patients received treatment for up to 18 months without cumulative toxicity.

Conclusion. Treatment with EMD72000 was well tolerated and showed evidence of activity in heavily pretreated patients with EGFR-expressing tumors. EMD72000 at the investigated doses significantly inhibited downstream EGFR-dependent processes.

Supported in part by a grant from Merck KGaA, Darmstadt.
Presented in part at the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002.

© 2004 American Society for Clinical Oncology